Backgound Hyperlipidemia has been highlighted as global chronic conditions of our time, the regulating spleen and lipid decoction (RSLD) is a traditional Chinese medicine preparation for hyperlipidemia with good therapeutic effect. This study used urinary metabolomics combined with network pharmacology to elucidate the mechanism of RSLD in treating hyperlipidemia.Methods In this study, the network pharmacology was used to dissect the impacts of RSLD on the hyperlipidemia network. Serum samples from hyperlipidaemic rats were collected to quantify biochemical indices, urinary metabolomics was used to evaluate urine samples from control, model, xuezhikang and RSLD groups to shed light on a metabolic mechanism of action.Results The component- target-disease network suggested that the low density lipoprotein receptor (LDLR) target protein, which is associated with hyperlipidemia, is regulated by RSLD. A metabolomics analysis suggested that RSLD can significantly regulates taurine, citric acid, leucine, valine and linoleic acid in amino acid metabolism, fatty acid metabolism and tricarboxylic acid cycle, and that the overall metabolic mechanism is closely related to the target protein LDLR.Conclusions Metabolomics combined with network pharmacology suggested that RSLD can improve hyperlipidemia by enhancing LDLR protein expression to regulate disordered biomarkers and their metabolic pathways. Therefore, we believe that RSLD represents an interesting candidate for further characterization as a treatment for hyperlipidemia.